<DOC>
	<DOCNO>NCT00145847</DOCNO>
	<brief_summary>The primary purpose study determine whether naltrexone effective treatment alcohol dependence abuse patient schizophrenia schizoaffective disorder . Hypotheses follow : hypothesis 1 : Naltrexone effective placebo reduce alcohol use . hypothesis 2 : Patients respond naltrexone reduce alcohol use also show reduction severity psychiatric symptom utilization inpatient emergency psychiatric service . hypothesis 3 : Severity psychiatric symptom amount service utilization correlate positively alcohol use .</brief_summary>
	<brief_title>Naltrexone Treatment Alcohol Abuse Schizophrenia</brief_title>
	<detailed_description>The long-term goal propose project improve treatment alcohol abuse dependence patient schizophrenia schizoaffective disorder . Alcohol use disorder common among patient severe mental illness . It estimate may many 750,000 individual United States comorbid schizophrenia alcohol disorder . Alcohol disorder comorbidity require treatment associated adverse consequence increase rate hospitalization . Yet , date , report control trial test efficacy pharmacological treatment alcohol abuse dependence population . Naltrexone pharmacotherapy effective treatment alcohol dependence , systematically apply care patient schizophrenia . The specific aim study : To test efficacy naltrexone reduce alcohol use among individual schizophrenia schizoaffective disorder also alcohol abuse dependence . We test hypothesis 1 : Naltrexone effective placebo reduce alcohol use . Our primary outcome measure number drinking day course treatment trial . To test naltrexone 's efficacy reduce psychiatric symptom severity medical utilization reduce alcohol use . We test hypothesis 2 : Patients respond naltrexone reduce alcohol use also show reduction severity psychiatric symptom utilization inpatient emergency psychiatric service . To determine relationship ) change alcohol use , b ) psychiatric symptom severity inpatient emergency service utilization . We test hypothesis 3 : Severity psychiatric symptom amount service utilization correlate positively alcohol use . The propose research study cohort 150 subject double-blind , randomize , placebo-controlled trial naltrexone use three time per week directly observe administration medication . The study 6 month duration , consist 12-week course naltrexone placebo plus 3 monthly follow-up interview discontinuation medication . Voucher incentives contingent attendance provide subject ensure attendance medication administration . Weekly motivational enhancement counseling session also provide subject . Study outcomes consist self-report biological measure alcohol use well measure psychiatric symptom severity medical service utilization .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Alcoholism</mesh_term>
	<mesh_term>Alcohol-Related Disorders</mesh_term>
	<mesh_term>Ethanol</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>1 . Males female , age 18 69 , DSMIV diagnosis Schizophrenia Schizoaffective Disorder ; 2 . DSMIV diagnosis Alcohol Abuse Alcohol Dependence ; 3 . Level Drinking : At least four day drink 30 day prior consent ; 4 . Currently prescribe antipsychotic medication ; 5 . Currently involved outpatient psychiatric treatment one study site ( Hutchings Psychiatric Center , St. Joseph 's Hospital Health Center , VA Medical Center ) another location community time randomization . 1 . Inability give adequate inform consent ; 2 . Currently take disulfiram ( Antabuse ) naltrexone ( ReVia/Depade ) ; 3 . Current DSMIV diagnosis Opioid Dependence Opioid Abuse ; 4 . Currently take ibuprofen potentially hepatotoxic medication amount and/or frequency judge Principal Investigator pose clinically significant add risk hepatic injury ; 5 . Current use prescribe nonprescribed opioid analgesic , methadone , morphine , codeine , heroin , meperidine , opioids . 6 . Female patient childbearing potential sexually active , sterile , deny use form birth control ; 7 . Female patient pregnant nursing ; 8 . Significant unstable medical problem , include significant unstable psychiatric disorder . The study physician conduct medical history physical exam exclude clinically unstable individual ; 9 . AST level great 3x upper limit normal ; 10 . Subjects attend require screening appointment . Subsequent exclusion study reason relate nonattendance base judgment principal investigator ; 11 . In need acute medical detoxification alcohol judgment study physician base result Clinical Institute Withdrawal Assessment Alcohol Scale Based DSMIIIR ( CIWAAD ) information obtain ; 12 . Scheduled surgery within 3 month intake ; 13 . Subjects pending legal proceeding whose outcome may lead incarceration within 3 month intake .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>alcohol</keyword>
	<keyword>schizophrenia</keyword>
	<keyword>naltrexone</keyword>
</DOC>